Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...

The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to ...

Early data in mice and human tissue indicate that using drugs or gene therapy could allow for cardiac healing in ischemic HF.

The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...

CV risk factors don’t just impact heart health, but also affect other organs, including the brain, say experts.

For many of these conditions, women present later and sicker, and are less likely to be treated appropriately.

More research is needed to see how this factor could inform risk tools and whether addressing it reduces future disease.

Poor performance on quality metrics carried greater risk of in-hospital mortality no matter where patients initially ...

For the investigator-initiated ATTENUATE trial, researchers used the 11 x 34” RADPAD Orange, which Medranda calls a ...

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...